Contact Us

Transparent Collaboration in Cell and Gene Therapy Outsourcing: Pioneering Efficiency and Innovation

August 30, 2023

In cell and gene therapy (CGT) development and manufacturing, the quest for efficiency and innovation is unceasing. As these therapies carve new pathways in medicine, the complexity of their processes poses unique challenges. For companies considering outsourcing, the need for transparency is paramount. Traditional paper-based and audit-centric collaboration models have proven inadequate for the intricacies of cell and gene therapy, often leading to opacities, inefficiencies, and issues that seemingly come out of the blue.

The shift to transparent outsourcing

Outsourcing cell and gene therapy development and manufacturing offers various benefits, from leveraging specialized expertise to streamlining operations. However, maintaining visibility and control over the process remains a concern. The “black box” nature of traditional outsourcing models can hinder effective decision-making and communication. Transparent collaboration addresses this challenge, providing real-time insights into the processes while nurturing collaborative partnerships.

Key technology investments as enablers

The foundation of transparent collaboration lies in strategic technology investments. Manufacturing Execution Systems (MES), data lakes, and in-process analytics are pivotal in this regard. These technologies ensure seamless data flow, real-time monitoring, and comprehensive process documentation. By integrating automation and AI, these investments enhance accuracy, efficiency, and the ability to detect anomalies.

In-suite camera and sensor systems

In the realm of cell and gene therapy, deviations and unexpected events can disrupt processes. In-suite camera and sensor systems on equipment and facilities play a critical role in capturing every facet of the manufacturing process. These systems provide real-time video feeds and sensor data, facilitating rapid deviation management and root cause analysis. Such transparency not only aids troubleshooting but also empowers a proactive approach to quality control.

Real-time access through dashboards and video feeds:

In the age of digital transformation, access to information is no longer confined to physical presence. Dashboards and video feeds offer real-time insights, allowing stakeholders to remotely monitor operations, assess progress, and identify potential bottlenecks. This digital accessibility augments in-person suite access and fosters seamless collaboration across geographies.

Seamless collaboration for efficient progress:

Transparent collaboration redefines the outsourcing paradigm. It bridges the gap between companies and CDMOs, fostering open communication, informed decision-making, and quicker issue resolution. This collaboration model empowers both sides with a deeper understanding of the processes, contributing to enhanced efficiencies and shortened timelines.

When partnering with a CDMO to develop advanced therapies, transparent collaboration emerges as a beacon of progress. The intricacies of cell and gene therapy development and manufacturing demand an innovative approach that transcends traditional models. By investing in technology, embracing real-time data, and leveraging remote access, companies can redefine the way they outsource. The result? Efficient, agile, and transparent collaborations that accelerate the journey from the laboratory to life-changing therapies for those in need. To delve deeper into the transformative potential of transparent collaboration, explore the insights shared in our on-demand webinar.

About The Center for Breakthrough Medicines (CBM)

Center for Breakthrough Medicines (CBM) is a purpose-built and patient-driven, cell and gene therapy contract development and manufacturing organization (CDMO) uniquely positioned to enable pharma and biotech companies to develop, test, and manufacture life-saving therapies on a global scale. Ideally located in the heart of Philadelphia’s Cellicon Valley, CBM has assembled the most accomplished cell and gene therapy experts in the world, armed with cutting-edge and innovative technologies, to offer scalable, end-to-end, best-in-class services from pre-clinical through commercial, including process development, plasmid DNA, vector manufacturing, cell banking, cell processing, and a full suite of complementary and standalone testing and analytical capabilities.

Contact Us Now